Coherus is a fully integrated commercial-stage innovative oncology company. Coherus, formerly known as Coherus BioSciences Inc., is based in REDWOOD CITY, Calif.
| Revenue (Most Recent Fiscal Year) | $266.96M |
| Net Income (Most Recent Fiscal Year) | $28.51M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 0.52 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | -- |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 3.02 |
| Pre-Tax Margin (Trailing 12 Months) | 24.88% |
| Net Margin (Trailing 12 Months) | -66.30% |
| Return on Equity (Trailing 12 Months) | -- |
| Return on Assets (Trailing 12 Months) | -26.51% |
| Current Ratio (Most Recent Fiscal Quarter) | 1.22 |
| Quick Ratio (Most Recent Fiscal Quarter) | 1.20 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | -- |
| Inventory Turnover (Trailing 12 Months) | 2.59 |
| Book Value per Share (Most Recent Fiscal Quarter) | $-1.14 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.41 |
| Earnings per Share (Most Recent Fiscal Year) | $0.25 |
| Diluted Earnings per Share (Trailing 12 Months) | $-1.13 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 115.93M |
| Free Float | 106.57M |
| Market Capitalization | $102.02M |
| Average Volume (Last 20 Days) | 1.17M |
| Beta (Past 60 Months) | 0.86 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 8.08% |
| Percentage Held By Institutions (Latest 13F Reports) | 72.82% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |